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Background: GPCR transactivation of PTKRs and TGF-Rs mediates proteoglycan synthesis in human VSMC.
Results: Transactivation of TGF-Rs is integrin-dependent, and inhibition of both transactivation pathways blocks proteogly-
can synthesis.
Conclusion: GPCR utilize transactivation pathways and not classical signaling in proteoglycan synthesis.
Significance:GPCR transactivation of receptor kinase pathways may be broader andmore significant than previously recognized.
G protein-coupled receptor signaling is mediated by three
main mechanisms of action; these are the classical pathway,
-arrestin scaffold signaling, and the transactivation of protein-
tyrosine kinase receptors such as those for EGF and PDGF.
Recently, it has been demonstrated that G protein-coupled
receptors can also mediate signals via transactivation of serine/
threonine kinase receptors, most notably the transforming
growth factor- receptor family. Atherosclerosis is character-
ized by the development of lipid-laden plaques in blood vessel
walls. Initiation of plaque development occurs via low density
lipoprotein retention in the neointima of vessels due to binding
with modified proteoglycans secreted by vascular smooth mus-
cle cells. Here we show that transactivation of protein-tyrosine
kinase receptors is mediated by matrix metalloproteinase triple
membrane bypass signaling. In contrast, serine/threonine
kinase receptor transactivation is mediated by a cytoskeletal
rearrangement-Rho kinase-integrin system, and both protein-
tyrosine kinase and serine/threonine kinase receptor transacti-
vation concomitantly account for the total proteoglycan synthe-
sis stimulated by thrombin in vascular smooth muscle. This
work provides evidence of thrombin-mediated proteoglycan
synthesis and paves theway for a potential therapeutic target for
plaque development and atherosclerosis.
G protein-coupled receptors (GPCR)3 represent the largest
group of cell surface receptors in mammalian biology and are
heavily implicated in physiology and pathology (1). They con-
tribute to a diverse array of functions in various cell types such
asmigration and proliferation, contraction, and fibrosis and are
prominent inmany disease states such as cancer, fibrotic disor-
ders, and cardiovascular disease (2). Cellular signaling byGPCR
occurs via three main mechanisms. The first is the “classical”
mechanism by which ligand activation leads to a conforma-
tional change in the receptor and the activation of intracellular
G protein  and  subunits and the propagation of signals
through secondary messengers such as phospholipase C (3).
The second is the utilization of -arrestin molecules that form
scaffold complexes and lead to intracellular signaling (4).
Finally, they can also signal via variousmembers of the protein-
tyrosine kinase receptor (PTKR) family such as the very well
documented EGF and PDGF receptors in a mechanism termed
“transactivation.” Transactivation results in the stimulation of
Erk1/2 and PI3K pathways allowing the GPCR to elicit full
mitogenic responses (5). Transactivation of PTKR was first
described byUllrich and colleagues (6) in 1996 and revealed the
transactivation of the epidermal growth factor receptor (EGFR)
by the GPCR agonists thrombin, angiotensin II, and endothe-
lin-1 (6). Since then PTKR transactivation has gained much
attention, and a more defined mechanism is beginning to
emerge. However, recent evidence demonstrates that transac-
tivation is not limited to PTKR but also includes serine/threo-
nine kinase receptors (S/TKR), namely those of the transform-
ing growth factor-(TGF)- family. TGF- signals via ligand
engagement of a receptor complex containing the type I recep-
tor Alk5, leading to phosphorylation of the immediate down-
stream Smad2/3 transcription factors (7). We and others have
recently demonstrated that GPCR such as thrombin, angioten-
sin II, endothelin-1, and lysophosphatidic acid lead to the time-
dependent generation of phosphorylated Smad2 (8–12).
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Atherosclerosis is themain underlying etiology in cardiovas-
cular disease and is characterized by the formation of atherom-
atous plaques in blood vesselwalls that can occlude the vessel or
becomeunstable and rupture, resulting in heart attack or stroke
and often death (13). The initiating event in plaque develop-
ment is described in the “response to retention hypothesis” of
atherogenesis in which retention of low density lipoproteins
(LDL) in the neointimal layer of blood vessel walls is due to
changes in the synthesis of extracellular matrix proteoglycans
secreted by vascular smooth muscle cells (VSMC) migrating
out of themedial layer (14, 15). VSMC exposed to various stim-
uli such as GPCR agonists, including thrombin, produce pro-
teoglycans with elongated glycosaminoglycan (GAG) chains,
which show higher binding affinity to LDL (16–21). We have
also demonstrated that thrombin utilizes both PTKR and
S/TKR transactivation in proteoglycan synthesis, but we had no
indication of whether these are independent, redundant, or
cooperative. Here we demonstrate that the two transactivation
pathways act independently in thrombin-stimulated proteogly-
can synthesis and that the two transactivation pathways, but
not traditional pathways, account for almost all of the actions of
thrombin on proteoglycan synthesis (see Fig. 8). Additionally,
we show that the mechanism of thrombin-stimulated transac-
tivation of TGF- receptor signaling involves cytoskeletal rear-
rangement, Rho kinase (ROCK) signaling, and cell surface RGD
binding integrins in human VSMC (see Fig. 8).
EXPERIMENTAL PROCEDURES
Materials—The following chemicals were purchased from
Sigma: thrombin, EGF, benzamidine hydrochloride, 6-amino-
caproic acid, DEAE-Sephacel, chondroitin sulfate, SB431542,
GM6001, Y27632, AG1478, cycloheximide, and cytochalasinD.
Dulbecco’s modified Eagle’s medium (DMEM) and glutamine
were fromGibco; fetal bovine serum (FBS) and penicillin strep-
tomycin fungizone were obtained from CSL (Parkville Austra-
lia); and carrier-free [35S]SO4 and [35S]methionine/cysteine
were obtained from MP Biomedicals. The synthetic RGD
(cGRGDSP) and RGE (RGES) peptides were fromAnaspec Inc.
(Fremont, CA). Cetylpyridinium chloride was from Unilab
Chemicals and Pharmaceuticals; Whatman 3MM chromatog-
raphy paper was from Biolab (Mulgrave, Australia); Insta-Gel
Plus scintillation fluid was from PerkinElmer Life Sciences; and
Poly-Prep columns were from Bio-Rad. Human recombinant
TGF- and anti-phosphorylated Smad2 (phosphoSmad2),
anti-total Smad2 (Smad2), anti-GAPDH (GAPDH), anti-phos-
phorylated Erk1/2 (phosphoErk1/2), anti-total Erk1/2 (Erk1/2),
and anti-phosphorylated Ezrin, Radixin, andMoesin (phospho-
ERM) rabbit monoclonal antibodies were from Cell Signaling
Technology (Danvers, MA). ECL detection reagents and HRP-
conjugated anti-rabbit IgGmonoclonal antibody were fromGE
Healthcare (Birmingham, UK). Alexa Fluor 488-phalloidin and
Hoechst stain were a generous gift from Dr. Simon Potocnik,
RMIT University.
Culture of Human VSMC—Human VSMCwere obtained by
the explant method (22) from discarded sections of saphenous
veins from coronary artery bypass grafting patients at the
Alfred Hospital, with approval by the Alfred Ethics committee.
VSMC were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) with 5 mM glucose, 10% fetal bovine serum
(FBS), and 1% penicillin-streptomycin-fungizone solution at
37 °C, 5%CO2. For experiments, VSMCwere seeded into 24- or
6-well plates, grown to confluence, and then rendered quies-
cent by serum deprivation for 48 h.
Western Blotting—Total cell lysates were collected and sepa-
rated on 10% acrylamide gel SDS-PAGE and transferred onto
nitrocellulose membranes. Membranes were blocked with 5%
skim milk powder and then incubated with anti-phosphoS-
mad2, anti-Smad2, anti-GAPDH, anti-phosphoErk1/2, anti-
Erk1/2, or anti-phosphoERM rabbit monoclonal antibody fol-
lowed by HRP-anti-rabbit IgG and ECL detection. Blots were
imaged using the Bio-Rad gel documentation system, and den-
sitometry analysis was performed with Quantity One imaging
software (Bio-Rad Laboratories) and normalized to basal for
-fold change determination.
Quantitation of De Novo Protein Synthesis—Quiescent cells
were changed to fresh medium containing 10 g/ml cyclohex-
imide, to which 10 Ci/ml was added, and the cells incubated
for 4 h. After 4 h, thrombin was added, and the cells were incu-
bated for a further 18 h. Cells were then washed with PBS and
incubated with 10% w/v TCA for 30 min on ice. TCA was
removed; cells were washed and then incubated with 0.1% SDS
in 0.1 N NaOH for 30 min at 37 °C with agitation. Cells were
then collected and added to scintillation fluid with 1% acetic
acid (1 M) and counted.
Confocal Imaging of the Actin Cytoskeleton—Cells were
grown on 1.5 grade glass coverslips and then rendered quies-
cent via serum deprivation. After treatments, cells were fixed in
2%paraformaldehyde in 1 Nphosphate buffer and thenpermea-
bilized and blocked in 0.1% Triton X-100, 1% horse serum for
30min. Cellswere incubatedwithAlexa Flour 488-phalloidin (a
generous gift from Dr. Simon Potocnik, RMIT University) and
Hoechst stain for 30min for the detection of the actin cytoskel-
eton and nucleus, respectively. Coverslips were then mounted
on slides, and cells were imaged using a Nikon D-eclipse C1
confocal microscope.
Quantitation of Proteoglycan Synthesis—Quiescent cells
were changed to fresh medium containing 50 Ci/ml [35S]sul-
fate in the presence or absence of thrombin, TGF-, or EGF for
24 h.Media from the cell cultures were harvested, and protease
inhibitors (5 mM benzamidine in 0.1 M 6-aminocaproic acid)
were added to prevent degradation. Incorporation of the radio-
label into proteoglycans was measured by cetylpyridinium
chloride precipitation assay, as described previously (23).
SDS-PAGE Analysis of Proteoglycan Size—Proteoglycans
labeled with [35S]sulfate were prepared for SDS-PAGE by iso-
lation through DEAE-Sephacel anionic exchange mini col-
umns. Samples were added to pre-equilibrated columns and
then washed extensively with low salt buffer (8 M urea, 0.25 M
NaCl, 2 mM disodium EDTA, 0.5% Triton X-100). Proteogly-
cans were eluted with high salt buffer (8 M urea, 3 MNaCl, 2mM
disodium EDTA, 0.5% Triton X-100), and fractions containing
the highest number of [35S]sulfate cpm were pooled. Aliquots
(25,000 cpm) were precipitated (1.3% potassium acetate, 95%
ethanol), and chondroitin sulfate was added as a “cold carrier.“
Samples were resuspended in buffer (8 M urea, 2 mM disodium
EDTA, pH 7.5), to which an equal volume of sample buffer was
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added. Radiolabeled proteoglycans were separated on 4–13%
acrylamide gels with a 3% stacking gel at 50 V overnight. Gels
were then fixed and dried and exposed to a phosphorimaging
screen (Fuji Photo Film Co.) for3 days and then scanned on a
bio-imaging analyzer BAS-1000 MacBas (Fuji Photo Film Co.).
Statistical Analysis—Data were normalized and expressed as
the mean S.E. Data were analyzed using a one-way ANOVA
and deemed significant at p 0.05.
RESULTS
We have previously demonstrated that the GPCR agonist
thrombin transactivates the TGF- receptor Alk5, leading to
the generation of phosphoSmad2(Ser465/467), and that this
plays a partial role in the synthesis of proteoglycans mediated
by thrombin stimulation in human VSMC (8). However, we
have no information on the intermediatemechanism that exists
between the GPCR, PAR-1, and Alk5. Accordingly, we asked
the question whether transactivation involves de novo protein
synthesis. To explore themechanism of transactivation, we uti-
lized the inhibitor of translation, cycloheximide. Thrombin
generated a temporal increase in levels of phospho-
Smad2(Ser465/467), beginning at 1 h and reaching amaximum
of 2.5-fold at 4 h (p 0.05) (Fig. 1A, lanes 1–4). The generation
of phosphoSmad2(Ser465/467) wasmaintained in the presence
of cycloheximide (10 g/ml) (Fig. 1A, lanes 5–7). As a control,
we demonstrate that de novo protein synthesis is not required
for the direct stimulation of phosphoSmad2(Ser465/467) by
TGF- at 1 h (Fig. 1A, lanes 8 and 9). To confirm that cyclohex-
imide inhibits protein synthesis in these cells under the condi-
tions of this experiment, a methionine/threonine radiolabel
([35S]Met/Cys) was used. Cycloheximide (10 g/ml) com-
pletely abolishes de novo protein synthesis in human VSMC
both in the presence and in the absence of thrombin (p 0.01)
as assessed by [35S]Met/Cys incorporation into total proteins in
human VSMC. This experiment shows that the stimulation of
phosphoSmad2 by thrombin does not require transcription/
translation.
The transactivation of PTKR relies largely on the well char-
acterized triple-membrane passing system. This involves the
stimulation of cell surface matrix metalloproteinases (MMP),
subsequently leading to the cleavage and generation of ligands
that bind and activate the PTKR in an autocrine/paracrine fash-
ion (24). It is known that in some cellular systems, membrane-
boundTGF- can be chemically cleaved and processed from its
latent form, allowing it to act on its receptor in a similarmanner
(25). To determine the possibility that thrombin may be acti-
vating Alk5 via the activation of MMP, we utilized the broad
spectrum MMP inhibitor GM6001. The 2-fold stimulation of
phosphoSmad2(Ser465/467) by thrombin in VSMC (p 0.01)
occurred in either the presence or the absence of GM6001 (10
M) (Fig. 2A, lanes 1–8). GM6001 did not inhibit TGF--stim-
ulated phosphoSmad2(Ser465/367) at 1 h as a control (Fig. 2A,
last two separate lanes). To confirmGM6001 as anMMP inhib-
itor, we directed it against the classical PTKR transactivation
model using phosphoErk1/2(Thr202/Tyr204) as readout as
phosphorylated Erk1/2 is typically described as the down-
stream product of EGFR transactivation. Thrombin stimulated
a 2-fold increase in phosphoErk1/2(Thr202/Tyr204) at 5 min
(p 0.01) in human VSMC (Fig. 2B, lanes 1 and 2). This stim-
ulation was completely abolished in the presence of GM6001
(10 M) (p  0.01) with the level of phosphoErk1/2(Thr202/
Tyr204) remaining at basal (Fig. 2B, lane 3). As a control, we
also show that GM6001 (10 M) has no effect on the ability of
EGF to directly stimulate its cognate receptor as it fails to
inhibit EGF stimulation of phosphoErk1/2(Thr202/Tyr204) at
5min (Fig. 2B, lanes 4 and 5). Taken together, this indicates that
thrombin does not transactivateAlk5 viaMMP-driven catalytic
cleavage andprocessing ofTGF- ligands in this context, or any
other MMP-dependent mechanism.
Thrombin is a recognized inducer of cytoskeletal rearrange-
ment. As such, we wished to determine the role of the cytoskel-
FIGURE 1. Thrombin-mediated stimulation of phosphoSmad2(Ser465/
467)doesnot requiredenovoprotein synthesis inhumanVSMC.A, VSMC
were preincubatedwith cycloheximide (CHX) (10g/ml) or vehicle for 30min
and then treated with thrombin (10 units/ml) for 1, 2, and 4 h. VSMC stimu-
latedwithTGF- (2ng/ml) for 1h in thepresenceor absenceof cycloheximide
(10g/ml)were used as controls. Cell lysateswere collected, andproteins (50
g)were resolvedover 10%acrylamidegel SDS-PAGEand then transferred to
a nitrocellulose membrane. The membrane was then incubated with anti-
phosphoSmad2(Ser465/467) (pSmad2(Ser465/467)) monoclonal antibody
(1:1000) followed by peroxidase-labeled anti-rabbit IgG secondary antibody.
Membranes were stripped and reincubated with anti-Smad2 monoclonal
antibody (1:1000) followed by peroxidase-labeled anti-rabbit IgG secondary
antibody and anti-GAPDH HRP-conjugated monoclonal antibody (1:10,000)
to determine equal loading. The gel is a representation of three separate
experiments. Histograms represent band density as -fold over basal from at
least three separate experiments. Data are expressed as mean  S.E. #, p 
0.05 versus untreated control using a one-way ANOVA. Quantitation of TGF-
bands is not included inpanel Adue to intensity, but no significant decrease is
detected. B, VSMC were incubated with cycloheximide (10 g/ml) and
[35S]Met/Cys (10 Ci/ml) for 4 h and then with thrombin (10 units/ml) for an
additional 16 h. Total proteinswere purified and precipitated using TCA (10%
w/v) followed by 0.1% SDS in 0.1 M NaOH, and radioactivity was measured.
The histogram is representative of two separate experiments in triplicate. ##,
p 0.01 versus untreated control using a one-way ANOVA.
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eton in the transactivation of Alk5 in VSMC. To test this, we
employed cytochalasin D, which is a potent inhibitor of actin
polymerization and also results in the destruction of the pre-
existing cytoskeleton. We pretreated VSMC with cytochalasin
D (10 M) for 30 min and assessed the ability of thrombin to
induce phosphorylation of Smad2. The stimulation of
phosphoSmad2(Ser465/467) by thrombin was completely
abolished at 1 and 2 h (p  0.05 at 2 h) in the presence of
cytochalasin D (Fig. 3A, lanes 6 and 7), suggesting that an
intact cytoskeleton is required for the transactivation of Alk5
at least at these time points. We did not observe decrease in
phosphoSmad2(Ser465/467) levels at 4 h in the presence of
cytochalasin D (Fig. 3A, lane 8). As a control, cytochalasin D
(10 M) did not inhibit TGF- stimulation of phospho-
Smad2(Ser465/467) at 1 h in human VSMC (Fig. 3A, last two
separate lanes). To confirm that cytochalasin D results in the
destruction of the cytoskeleton in VSMC, we evaluated cyto-
skeletal integrity by tagging with an Alexa Fluor 488-phalloi-
din fusion protein that binds to all cytosolic actin, in both the
presence and the absence of cytochalasin D (10 M). Conflu-
ent, quiescent VSMC in culture display typical morphology
with actin filaments seen as an ordered striated architecture
within the cells, visualized using confocal microscopy (Fig.
3B, panel i). However, incubation with cytochalasin D at 1, 2,
and 4 h results in complete destruction of the actin cytoskel-
eton as evidenced by the unordered, globular appearance of
the actin, which is no longer filamentous in morphology (Fig.
3B, panels ii–iv). Thus, cytochalasin D (10 M) is successful
in destroying the cytoskeleton in human VSMC as early as
1 h and is maintained to at least 4 h.
The family of small Rho GTPases and their downstream tar-
get ROCK are implicated in cytoskeletal signaling induced by
thrombin (26). Having provided evidence for cytoskeletal
involvement in Alk5 transactivation, we sought to determine a
possible role of ROCK signaling. We used the small molecule
inhibitor of ROCK, Y27632. VSMC were incubated with
Y27632 (10M) for 30minprior to thrombin exposure. Throm-
bin stimulation resulted in the temporal increase in
phosphoSmad2(Ser465/467) at 1, 2, and 4 h (p 0.01) (Fig. 4A,
lanes 1–4). This stimulation was abolished in the presence of
FIGURE 2. Thrombin-mediated stimulation of phosphoSmad2(Ser465/467) is not dependent onMMP-induced shedding of TGF- ligands in human
VSMC. A, VSMCwere preincubated with GM6001 (10M) or vehicle for 30 min and then exposed to thrombin (10 units/ml) for 1, 2, and 4 h. VSMC stimulated
with TGF- (2 ng/ml) for 1h in thepresenceor absenceofGM6001 (10M)wereusedas controls. Cell lysateswere collected, andproteins (50g)were resolved
over 10%acrylamide gel SDS-PAGE and then transferred to a nitrocellulosemembrane. Themembranewas then incubatedwith anti-phosphoSmad2(Ser465/
467) (pSmad2(Ser465/467)) monoclonal antibody (1:1000) followed by peroxidase-labeled anti-rabbit IgG secondary antibody. Membranes were stripped and
reincubated with anti-Smad2monoclonal antibody (1:1000) followed by peroxidase-labeled anti-rabbit IgG secondary antibody and anti-GAPDH HRP-conju-
gatedmonoclonal antibody (1:10,000) to determine equal loading. B, VSMCwere preincubated with GM6001 (10M) or vehicle for 30 min and then exposed
to thrombin (10 units/ml) or EGF (100 nM) for 5 min. Proteins were collected, separated, and transferred to membranes as above. The membrane was then
incubated with anti-phosphoErk1/2(Thr202/Tyr204) (pERK1/2(Thr202/Tyr204)) monoclonal antibody (1:1000) followed by peroxidase-labeled anti-rabbit IgG
secondary antibody. Membranes were stripped and reincubated with anti-Erk1/2 monoclonal antibody (1:1000) followed by peroxidase-labeled anti-rabbit
IgG secondary antibody to determine equal loading. In both A and B are representatives of three separate experiments. Histograms represent band density as
-fold over basal from at least three separate experiments. Data are expressed asmean S.E. ##, p 0.01 versus untreated control. **, p 0.01 versus thrombin
treated using a one-way ANOVA. Quantitation of TGF- bands is not included in panel A due to intensity, but no significant decrease is detected.
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Y27632 at all assayed time points (p 0.01 at 4 h) (Fig. 4A, lanes
5–7). Y27632 had no effect on the ability of TGF- to stimulate
phosphoSmad2(Ser465/467) (Fig. 4A, lanes 8 and 9). To con-
firm that Y27632 successfully inhibits ROCK activity in these
cells, we directed it against the immediate downstreamproduct
of ROCK, the group of three homologous proteins Ezrin,
Radixin, and Moesin (ERM). Firstly, we established the time
course of phosphoERM(Thr567/564/558) stimulation by
thrombin. Thrombin stimulation results in rapid 10-fold gen-
eration of phosphoERM(Thr567/564/558) at 2, 5, and 10 min
(p  0.01), starting to fall at 30 min (p  0.05) (Fig. 4B). We
assessed the inhibitory effect of Y27632 at 2min due to the early
but strong stimulation of phosphoERM(Thr567/564/558).
Thrombin stimulation of phosphoERM(Thr567/564/558) at 2
min (p 0.01) is completely inhibited by Y27632 (10 M) (p
0.01), indicating that Y27632 is a competent inhibitor of ROCK
and that ROCK signaling is involved in the thrombin-mediated
transactivation of Alk5.
Latent TGF- can be activated by various members of the
integrin family of cell surface molecules (27–30). Inside out
integrin signaling has been associated with cytoskeletal rear-
rangement and ROCK signaling cascades. Taking into account
the relationship of the integrins and cytoskeleton/ROCK sig-
naling and the RGD (Arg-Gly-Asp motif) binding properties,
integrins make a likely candidate for a key player in the trans-
activation of Alk5. To assess this, we used a small synthetic
RGD peptide that binds to RGD binding integrins, preventing
them from binding to further RGD sites, disabling potential
integrin extracellular cross-linking. We assessed the effect of
integrin blockade using an RGD peptide on thrombin stimula-
tion of phosphoSmad2(Ser465/467) at 1 and 4 h for early and
late phase analysis. Treatment of VSMC with the RGD pep-
tide had limited effect on thrombin-stimulated phospho-
Smad2(Ser465/467) at 50 and 100 M but displays a mild
inhibitory effect at 1 h and almost full inhibition at 4 h at 200
M (p  0.05) (Fig. 5A, lanes 1–9). As a control, we utilized
an analogous RGE (Arg-Gly-Glu) peptide, which is RGD
binding-defective. The peptide failed to inhibit thrombin-
generated phosphoSmad2(Ser465/467) (Fig. 5A, lanes 10
and 11). Additionally, we wished to determine whether
PTKR transactivation was integrin-dependent to elucidate
whether there is a common feature between PTKR and
S/TKR transactivation or whether they are controlled by dis-
tinct mechanisms. Thrombin stimulated a 2-fold increase in
phosphoErk1/2(Thr202/Tyr204) at 5 min that was main-
tained in the presence of RGD (200 M) peptide preincu-
bated for 30 min; this was also seen in the control RGE pep-
tide (200 M) at (Fig. 5B). Taken together, these data suggest
that thrombin transactivation of Alk5 leading to the gener-
ation of phosphoSmad2(Ser465/467) is mediated by cyto-
skeletal rearrangement and the ROCK/integrin axis in
human VSMC.
The modification of proteoglycans secreted by VSMC such
that they exhibit increased GAG elongation is an initiating
event in the development of atherosclerosis due to the binding
and retention of LDL in the vessel wall (15).We have previously
shown that thrombin-treated cells produce proteoglycans with
increased GAG chain length when analyzed by SDS-PAGE and
size exclusion chromatography of chemically liberated free
GAG chains from core proteins or free GAG chains induced by
the addition of exogenous xyloside (16).We have furthered this
to show that thrombin-mediatedGAG elongation is blocked by
inhibition of both PTKR (EGFR) (16) and S/TKR (Alk5) (8)
using the small molecule inhibitors AG1478 and SB431542,
respectively. However, in either case, we have only observed an
50% inhibition at the maximum concentration used with
either inhibitor. This led us to investigate the possibility of the
dual transactivation pathways working in tandem in thrombin-
mediated proteoglycan synthesis. To assess the roles of the
transactivation pathways, we used the inhibitors of EGFR
and Alk5, AG1478 and SB431542, respectively. We com-
menced by confirming the validity of these inhibitors on
their respective targets as well as the possibility of cross-
FIGURE 3.Cytoskeletal integrity is required for thrombin-mediated stim-
ulation of phosphoSmad2(Ser465/467) in human VSMC. A, VSMC were
preincubated with cytochalasin D (10 M) or vehicle for 30 min and then
exposed to thrombin (10 units/ml) for 1, 2, and 4 h. Stimulation by TGF- (2
ng/ml) for 1 h in the presence or absence of cytochalasin D (10M) was used
as control. Cell lysates were collected, and proteins (50 g) were resolved
over 10% acrylamide gel SDS-PAGE and then transferred to a nitrocellulose
membrane. The membrane was then incubated with anti-phos-
phoSmad2(Ser465/467) (pSmad2(Ser465/467))monoclonal antibody (1:1000)
followed by peroxidase-labeled anti-rabbit IgG secondary antibody. Mem-
branes were stripped and reincubated with anti-Smad2 monoclonal anti-
body (1:1000) followedbyperoxidase-labeled anti-rabbit IgG secondary anti-
body and anti-GAPDH HRP-conjugated monoclonal antibody (1:10,000) to
determine equal loading. The gel is a representation of three separate exper-
iments. Histograms represent band density as -fold over basal from at least
three separate experiments. Data are expressed as mean  S.E. #, p  0.05
versusuntreated control, and ##, p 0.01 versusuntreated control. *, p 0.05
versus thrombin-treated using a one-way ANOVA. Quantitation of TGF-
bands is not included inpanel Adue to intensity, but no significant decrease is
detected. B, VSMCwere grownon coverslips and treatedwith 10M cytocha-
lasin D (Cyto D) for 1 (panel ii), 2 (panel iii), and 4 h (panel iv) or vehicle (panel i).
Cells were fixed with 2% paraformaldehyde, permeabilized, and incubated
with or without (panel v) Alexa Fluor 488-phalloidin and Hoechst nuclear
counterstain. Cells were imaged using a Nikon D-eclipse C1 confocal micro-
scope. Images are representative of two independent experiments.
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reactivity. Experiments showed that AG1478 (1 and 5 M)
inhibits thrombin-mediated phosphoErk1/2(hr202/Tyr204)
stimulation (p  0.01) (Fig. 6A, lanes 1–4) as a readout of
PTKR transactivation, whereas SB431542 (3 M) fails to
cause inhibition (Fig. 6A, lane 5). As a positive control,
AG1478 (5 M) also successfully inhibited EGF-stimulated
phosphoErk1/2(Thr202/Tyr204) at 5min (p 0.01) (Fig. 6A,
lanes 6 and 7), indicating that it is an effective EGFR inhibi-
tor. Conversely, thrombin stimulation of VSMC for 4 h
results in a 2-fold increase in phosphoSmad2(Ser465/467)
(p  0.01), which is completely inhibited by SB431542 (p 
0.01) (1 and 3 M, Fig. 6B, lanes 1–4) but is unaffected by
AG1478 (5 M, Fig. 6B, lane 5). As a control, we show that
SB431542 (3 M) inhibits TGF--stimulated phospho-
Smad2(Ser465/467) (p  0.01) (Fig. 6B, lanes 6 and 7), indi-
cating that it is an effective Alk5 inhibitor. It is noteworthy
that the response is far greater in the presence of TGF- than
that of thrombin; thus, SB431542 failed to completely inhibit
TGF--stimulated phosphoSmad2(Ser465/467) at 3 M. A
concentration of 10 M SB431542 would have been optimal
for inhibition of TGF-; however, we chose to use 3 M to
maintain consistency. Having shown that the inhibitors
inhibit their respective targets but do not cross-react, we
then used them concomitantly and measured thrombin-me-
diated proteoglycan synthesis.
Incorporation of radioactive sulfate ([35S]sulfate) into
secreted proteoglycans is used as a measure of total proteogly-
can synthesis and represents the combination of core protein
expression and incorporation of sulfate into GAG chains, giv-
ing an indication of GAG elongation (31). Treatment of VSMC
with thrombin caused a 57% increase in [35S]sulfate incorpora-
tion into secreted proteoglycans (p 0.01), which was partially
inhibited by 84% in the presence ofAG1478 (5M) (p 0.01) or
68% in the presence of SB431542 (3 M) (p  0.01) alone as
described previously (8, 16). In the presence of both AG1478 (5
M) and SB431542 (3 M) simultaneously, the stimulation of
[35S]sulfate incorporation was reduced to the basal level (p 
0.01) (Fig. 7A). We used EGF and TGF- stimulation as con-
trols to show that both receptor types were active in these cells.
Stimulation with EGF and TGF- caused a 71 and 102% induc-
tion of [35S]sulfate incorporation, respectively, in these cells
(p 0.01) (Fig. 7A) when compared with thrombin. The afore-
FIGURE 4. Thrombin-mediated stimulation of phosphoSmad2(Ser465/467) requires ROCK signaling in human VSMC. A, VSMCwere preincubated with
Y27632 (10 M) or vehicle for 30 min and then exposed to thrombin (10 units/ml) for 1, 2, and 4 h. Stimulation by TGF- (2 ng/ml) for 1 h in the presence or
absence of Y27632 (10 M) was used as control. Cell lysates were collected, and proteins (50 g) were resolved over 10% acrylamide gel SDS-PAGE and then
transferred to a nitrocellulose membrane. The membrane was then incubated with anti-phosphoSmad2(Ser465/467) (pSmad2(Ser465/467)) monoclonal
antibody (1:1000) followed by peroxidase-labeled anti-rabbit IgG secondary antibody. Membraneswere stripped and reincubatedwith anti-Smad2monoclo-
nal antibody (1:1000) followedbyperoxidase-labeled anti-rabbit IgG secondary antibody and anti-GAPDHHRP-conjugatedmonoclonal antibody (1:10,000) to
determine equal loading. B, VSMCwere treatedwith thrombin (10 units/ml) for 2, 5, 10, and 30min. C, VSMCwere preincubatedwith Y27632 (10M) or vehicle
and then treated with thrombin (10 units/ml) for 2 min. For gels B and C, cell lysates were collected, separated, and transferred to a nitrocellulose membrane
as above. Membranes was then incubated with anti-phosphoERM(Thr567/564/558) (pERM(Thr567/564/558)) monoclonal antibody (1:1000) followed by per-
oxidase-labeled anti-rabbit IgG secondary antibody and anti-GAPDHHRP-conjugatedmonoclonal antibody (1:10,000) to determine equal loading. Panels A–C
are representative of at least three independent experiments. Histograms represent band density as -fold over basal from at least three separate experiments.
Data are expressed asmean S.E. ##, p 0.01 versus untreated control, and #, p 0.05 versus untreated control. **, p 0.01 versus thrombin-treated using a
one-way ANOVA. Quantitation of TGF- bands is not included in panel A due to intensity, but no significant decrease is detected
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mentioned increase in [35S]sulfate incorporation (Fig. 7A), as
described before, results from an increase in expression of pro-
teoglycan core proteins and GAG elongation. However, we
chose only to examine the effect onGAGelongation as it relates
to the increase in LDL binding and the development of athero-
sclerosis. To achieve this, proteoglycans were eluted using
DEAE-Sepharose ion-exchange and resolved over SDS-PAGE.
This demonstrates a change in size of the proteoglycans that
can only be due to a shift in size of the GAG chains as core
proteins have a conserved molecular weight. SDS-PAGE anal-
ysis of proteoglycan size reveals a similar pattern to that seen
with the [35S]sulfate incorporation (Fig. 7A), revealing that
thrombin treatment of VSMC results in proteoglycans, specif-
ically biglycan, with decreased electrophoretic mobility (Fig.
7B, lanes 1 and 3), corresponding to increasedGAG elongation.
This is also demonstrated with the co-incubation of the inhib-
FIGURE 5. Stimulation of phosphoSmad2(Ser465/467) but not phospho-
Erk1/2(Thr202/Tyr204) by thrombin is mediated by cell surface integ-
rins. A, VSMC were preincubated with 50, 100, or 200 M RGD peptide or
vehicle for 30 min and then treated with thrombin (10 units/ml) for 1 or 4 h.
VSMC preincubated with 200 M RGE peptide for 30 min followed by throm-
bin (10 units/ml) stimulation were used as a negative control. Cell lysates
were collected, and proteins (50 g) were resolved over 10% acrylamide gel
SDS-PAGE and then transferred to a nitrocellulose membrane. The mem-
brane was then incubated with anti-phosphoSmad2(Ser465/467)
(pSmad2(Ser465/467))monoclonal antibody (1:1000) followedbyperoxidase-
labeled anti-rabbit IgG secondary antibody. Membranes were stripped and
reincubatedwith anti-Smad2monoclonal antibody (1:1000) followedby per-
oxidase-labeled anti-rabbit IgG secondary antibody and anti-GAPDH HRP-
conjugated monoclonal antibody (1:10,000) to determine equal loading. B,
VSMC were preincubated with 200 M RGD, 200 M RGE peptides, or vehicle
for 30min and then exposed to thrombin for 5min. Proteins were harvested,
separated, and transferred tomembranes as above. Themembranewas then
incubated with anti-phosphoErk1/2(Thr202/Tyr204) (pERK1/2(Thr202/
Tyr204)) monoclonal antibody (1:1000) followed by peroxidase-labeled anti-
rabbit IgG secondary antibody. Membranes were stripped and reincubated
with anti-Erk1/2 (1:1000) monoclonal antibody followed by peroxidase-la-
beled anti-rabbit IgG secondary antibody to determine equal loading. Panels
A and B are representative of at least three independent experiments. Histo-
grams represent band density as -fold over basal from at least three separate
experiments. Data are expressed asmean S.E. ##, p 0.01 versus untreated
control. *, p 0.05 versus thrombin-treated using a one-way ANOVA.
FIGURE 6. AG1478 inhibits EGFR transactivation but not Alk5, and
SB431542 inhibits Alk5 transactivation but not EGFR. A, VSMC were pre-
incubatedwith either 1 or 5MAG1478, 3M SB431542 (SB), or vehicle for 30
min followed by treatment with thrombin (10 units/ml) for 5 min. 5 min EGF
(100 nM) stimulation in the presence or absence of 5M AG1478 was used as
a positive control. Lysates were collected and separated (50 g of protein)
over 10% acrylamide gel SDS-PAGE followed by transfer onto a nitrocellulose
membrane. Themembranewas incubatedwith anti-phosphoErk1/2(Thr202/
Tyr204) (pERK1/2(Thr202/Tyr204)) (1:1000) monoclonal antibody and then
peroxidase-labeled anti-rabbit IgG secondary antibody. The membrane was
stripped and reincubatedwith anti-Erk1/2 (1:1000) monoclonal antibody fol-
lowed by peroxidase-labeled anti-rabbit IgG secondary antibody for equal
loading determination. B, VSMC were preincubated with either 1 or 3 M
SB431542, 5 M AG1478 (AG), or vehicle for 30 min followed by treatment
with thrombin (10 units/ml) for 4 h. 1-h TGF- (2 ng/ml) stimulation in the
presence or absence of 3 M SB431542 was used as a positive control.
Lysates were collected, separated, and transferred to a nitrocellulose
membrane as above. The membrane was then incubated with anti-
phosphoSmad2(Ser465/467) (pSmad2(Ser465/467)) monoclonal antibody
(1:1000) followed by peroxidase-labeled anti-rabbit IgG secondary anti-
body.Membraneswere strippedand reincubatedwith anti-Smad2monoclo-
nal antibody (1:1000) followedby peroxidase-labeled anti-rabbit IgG second-
ary antibody and anti-GAPDH HRP-conjugated monoclonal antibody
(1:10,000) to determine equal loading. Panels A and B are representative of at
least three independent experiments. Histograms represent band density as
-fold over basal from at least three separate experiments. ##, p 0.01 versus
untreated control. **, p 0.01 versus thrombin- or EGF-treated using a one-
way ANOVA. Quantitation of TGF- bands is not included in panel B due to
intensity, but SB431542 caused a significant decrease in phosphoSmad2
when compared with TGF--treated (p 0.01).
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itors AG1478 (5 M) and SB431542 (3 M), which results in
biglycan with GAG chains similar to that of untreated control
(Fig. 7B, lane 6). The controls TGF- and EGF also result in
GAG elongation (Fig. 7B, lanes 7 and 8). The SDS-PAGE gel
was subject to densitometric analysis to quantify the shift in
biglycan peak (Fig. 7C). The graph demonstrates that the mean
peak for control is shifted with thrombin treatment, indicating
an increase in proteoglycan size, but lines upwith control in the
presence of AG1478 and SB431542 (Fig. 7C). This demon-
strates that thrombin utilizes both PTKR and S/TKR transacti-
vation pathways in eliciting its full responsewith regard toGAG
elongation in human VSMC.
DISCUSSION
Here we provide evidence that thrombin acting through its
GPCR, PAR-1, mediates transactivation of both PTKR and
S/TKR via distinct mechanisms and that both transactivation
pathways contribute to proteoglycan synthesis (andGAG elon-
gation) in human VSMC. The two transactivation pathways,
tyrosine and serine/threonine kinase, account for all of the sig-
naling of the action of thrombin on proteoglycan synthesis in
these cells. We demonstrate that thrombin stimulation of
phosphoSmad2(Ser465/467) requires an intact cytoskeleton
and is abolished in the presence of the small molecule ROCK
inhibitor Y27632.We also show that RGDbinding integrins are
involved in Alk5 transactivation as the presence of a synthetic
RGD peptide blunts stimulation; however, the specific isoform
remains to be determined.
In addition to classical signaling, GPCR can hijack and utilize
PTKR to broaden the scope of their cellular responses. This
phenomenon was first described in themid-1990s with the dis-
covery of EGFR transactivation (6) and since then has been
expanded to include a variety of other receptors, including
those for PDGF, insulin-like growth factor (IGF), NGF, and
FGF andmultiple mechanisms both ligand-dependent (24) and
ligand-independent (32) that are generally cell- and context-
specific. The transactivation of PTKR is relatively well charac-
terized; however, work in the last decade has demonstrated
transactivation of receptors from the TGF- family, which sig-
nal through S/TK activity. Sheppard and colleagues (10, 11)
have shown that in mouse lung epithelial cells, thrombin
and lysophosphatidic acid stimulate phosphorylation of
phosphoSmad2(Ser465/467) by 1 h and reaching amaximumat
4 h. This was demonstrated to be dependent on RhoA/ROCK
and the V6 integrin signaling. Furthermore, one study has
provided evidence for serotonin transactivation of BMP recep-
tors in mouse pulmonary artery smoothmuscle cells (33). Here
serotonin via its GPCR 5-hydroxytryptophan 1B/1D activates
BMPR1A, leading to the rapid generation of phosphoSmad1,
-5, and -8, which is also sensitive to ROCK inhibition, albeit a
role for integrinswas not examined (33).Our previouswork has
demonstrated that thrombin and endothelin-1 stimulate
increases in phosphoSmad2(Ser465/467) in human VSMC
similarly to that of mouse lung epithelial cells (8, 9); however,
until now the mechanism by which this is mediated was
unknown. This study provides evidence that thrombin stimu-
lates phosphoSmad2 in human VSMC via a similar mechanism
to that in mouse lung epithelial cells.
We attempted to evaluate the role of V3 in this study but
found that this integrin is unlikely to be involved as preincuba-
tion with an V3-specific RGD peptide or blocking antibody
failed to inhibit thrombin-stimulated phosphoSmad2(Ser465/
467) (data not shown). We do not have information on the
specific integrin that is responsible for Alk5 transactivation in
these cells; however, the latency-associated peptide found in
FIGURE 7. Thrombin stimulation of GAG elongation on biglycan is medi-
ated by cooperation of both PTKR and S/TKR pathways in humanVSMC.
A, VSMCwere treatedwith 3MSB431542, 5MAG1478, or in thepresenceof
both thrombin (10 units/ml) and [35S]SO4 (50 Ci/ml) for 24 h. EGF (100 nM)
and TGF- (2 ng/ml) were used as positive controls. An equal proportion of
media containing secreted proteoglycans was spotted ontoWhatman paper
and precipitated with cetylpyridinium chloride, as outlined under “Experi-
mental Procedures” for assessment of radiolabel incorporation. B, secreted
proteoglycans were purified from remaining media using DEAE ion-ex-
change chromatography and concentratedusing ethanol/potassiumacetate
precipitation. Electrophoretic mobility relating to overall proteoglycan size
was assessed by SDS-PAGE over a 4–13% acrylamide gradient gel. Biglycan is
seen as the proteoglycan of interest and is representative of three identical
experiments. Data are expressed as mean S.E. normalized to control from
three separate experiments in triplicate. ## p 0.01 versus untreated control.
**, p 0.01 versus thrombin-treated, using a one-wayANOVA.C, densitomet-
ric analysis of thegel inB. Thebroken line represents themid-point in thepeak
of the control biglycan band, for comparison of the shift in the peak location
from the treated samples.
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the LLC can bind, in theory, to all RGD binding integrins
including allV integrins,II3,51, and81. LAP binding
to integrins has officially been described for allV integrins and
81 (although the latter fails to lead to activation) (34); thus,
future studies should endeavor to uncover the specific integ-
rin(s) required for Alk5 transactivation in human VSMC. We
have shown that thrombin transactivates Alk5 via cytoskeletal
rearrangement, ROCK, and integrin signaling, butwewished to
determine the possibility that PTKR transactivation may also
be mediated by this mechanism, giving both PTKR and S/TKR
transactivation a common linking intermediate. -Opioid
receptors have been shown to transactivate EGFR in HEK293
(35) cells and TrkA receptors in neuroblastoma cells (36), and
in both situations, this was terminated with exogenous RGD
peptides, indicating integrin involvement. However, thrombin
treatment of humanVSMC in the presence of Y27632 andRGD
peptides failed to inhibit stimulation of phosphoErk1/2, sug-
gesting that in these cells, PTKR transactivation is not ROCK/
integrin-dependent. Thrombin stimulation of phosphoErk1/
2(Thr202/Tyr204) was completely abolished by the MMP
inhibitor GM6001 and the EGFR inhibitor AG1478, indicating
that the PTKR transactivation in these cells follows the well
characterized MMP-mediated triple-membrane passing
system of activation. Conversely, thrombin stimulation of
phosphoSmad2(Ser465/467) was unperturbed by GM6001,
suggesting that Alk5 transactivation is not dependent onmem-
brane shedding of TGF- ligands. Together the data show that
in human VSMC PTKR (EGF), transactivation by thrombin is
mediated by the typical ligand-dependent mechanisms,
whereas S/TKR (Alk5) transactivation is mediated by a cyto-
skeletal/ROCK/integrin axis. It is unknown exactly how integ-
rin signaling manifests in Alk5 activation; however, a mecha-
nism has been proposed that sees the pathway somewhat
restricted to the extracellular surface and is as follows. The
GPCR activates Rho/ROCK signaling via cytoskeletal rear-
rangement, leading to integrin activation via a shift in tensile
force. Activated integrin binds to the LLC at the RGD site, lead-
ing to a conformational change in the LLC, exposing theTGF-
ligand. The ligand is then free to engageAlk5 and initiate down-
stream signaling (29).
GAG elongation of proteoglycans synthesized by VSMC
such that they exhibit increased LDL binding is the initiating
factor in atherosclerotic plaque development (15, 37, 38). Our
laboratory has described the action of GPCR agonists in GAG
elongation, and we have shown that thrombin mediates part of
this response via Alk5 transactivation (8) and part of this
response via PTKR transactivation but not via classical signal-
ing (16). In this study, we reveal that simultaneous pharmaco-
logical inhibition of PTKR andAlk5 accounts for the total GAG
elongation output by thrombin-treated human VSMC. We
show that a physiological readout of proteoglycan synthesis is
mediated by the synergistic actions of the independent transac-
tivation pathways from the same GPCR. Knowing that these
effects are additive yet share no common intermediate in GAG
elongation means that the development of a therapeutic agent
for the prevention of plaque development will have to consider
these partial bypass mechanisms of the GPCR.
In summary, this study demonstrates that thrombin activates
the GPCR PAR-1, which transactivates PTKR and S/TKR via
two distinct mechanisms in human VSMC (Fig. 8). We show
here that PTKR (EGFR at least) is driven by theMMP-mediated
ligand-dependent mechanism, whereas Alk5 transactivation is
mediated by a dynamic cytoskeletal3 ROCK3 integrin inter-
play (Fig. 8). Additionally, we provide evidence that thrombin
utilizes both of these pathways in an additive manner in the
GAG elongation of biglycan (Fig. 8), revealing that the transac-
tivation pathways are themajor signaling cascades employed in
this regard. Notwithstanding that we have shown this in the
context of biglycan synthesis, it surely has broader therapeutic
utility in pathology such as acute lung injury (10, 11) andwound
healing (39) in which these interactions are known to be highly
active. This broadening in the current understanding of the
GPCR transactivation phenomenon will provide a change in
thinking in the way that medical therapies are developed,
knowing that many more and indeed novel GPCR signaling
pathways are activated than previously recognized, and this
represents both a challenge and an opportunity for interrupting
the pathophysiological actions of GPCR.
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